Complement C5 C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5 Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500
Complement C5 C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5 Pipeline Review, H2 2017
Summary
Complement C5 C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5 Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5bC6 complex is the foundation upon which the lytic complex is assembled. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.
Complement C5 C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5 pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in PreRegistration, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 5, 1 and 16 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Immunology, Hematological Disorders, Gastrointestinal, Ophthalmology, Cardiovascular, Infectious Disease, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Respiratory, Genetic Disorders and Other Diseases which include indications Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome Nondiarrhea Associated Hemolytic Uremic Syndrome, Chronic Inflammation, Myasthenia Gravis, Sepsis, Age Related Macular Degeneration, Choroidal Neovascularization, Dry Atrophic Macular Degeneration, Inflammation, Intermediate Uveitis, Lupus Nephritis, Posterior Uveitis, Septic Shock, Acute Lung Injury, Acute Renal Failure ARF Acute Kidney Injury, Autoimmune Disorders, Bacterial Pneumonia, Bacterial Sepsis, Benign Mucous Membrane Pemphigoid Oral Cicatricial Pemphigoid, Bullous Pemphigoid, Cardiovascular Inflammation, Community Acquired Pneumonia, Duchenne Muscular Dystrophy, EndStage Kidney Disease EndStage Renal Disease or ESRD, GuillainBarre Syndrome, Hidradenitis Suppurativa, Ischemia, Ischemia Reperfusion Injury, Juvenile Macular Degeneration Stargardt Disease, Kidney Transplant Rejection, Lung Injury, Multiple Organ Failure, Neuromyelitis Optica Devic's Syndrome, Peritonitis, Polypoidal Choroidal Vasculopathy, Pulmonary Edema, Sicca Syndrome Sjogren, Thrombotic Microangiopathy, Typical Hemolytic Uremic Syndrome ShigaToxin Associated Hemolytic Uremic Syndrome, Uveitis and Wet Neovascular / Exudative Macular Degeneration.
The latest report Complement C5 Pipeline Review, H2 2017, outlays comprehensive information on the Complement C5 C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Complement C5 C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Complement C5 C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5
The report reviews Complement C5 C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Complement C5 C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5 targeted therapeutics and enlists all their major and minor projects
The report assesses Complement C5 C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Complement C5 C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Complement C5 C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Complement C5 C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Original Article: Complement C5 C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5 Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500
